Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Payables (2023 - 2025)

Metagenomi (MGX) has disclosed Payables for 3 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 179.36% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 179.36% increase, with the full-year FY2025 number at $1.5 million, up 179.36% from a year prior.
  • Payables was $1.5 million for Q4 2025 at Metagenomi, up from $1.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.8 million in Q1 2024 to a low of $533000.0 in Q4 2024.
  • A 3-year average of $2.7 million and a median of $2.7 million in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 70.24% in 2024, then skyrocketed 179.36% in 2025.
  • Metagenomi's Payables stood at $1.8 million in 2023, then plummeted by 70.24% to $533000.0 in 2024, then surged by 179.36% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Payables are $1.5 million (Q4 2025), $1.2 million (Q3 2025), and $2.9 million (Q2 2025).